Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Subcutaneous panniculitis-like T-cell lymphoma 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Graft vs Host Disease 1

Interventions

fludarabine phosphate 19Peripheral Blood Stem Cell Transplantation 17Whole-Body Irradiation 15Mycophenolic Acid 14Cyclophosphamide 14Cyclosporine 12Busulfan 12Methotrexate 9Etoposide 9Tacrolimus 8Bortezomib 7Antilymphocyte Serum 7Everolimus 5Dexamethasone 5Vorinostat 4Rituximab 4Panobinostat 4Gemcitabine 4Flow Cytometry 4Carboplatin 4thymoglobulin 3Transplantation 3Therapeutics 3Radiotherapy 3Pharmacogenomic Testing 3Methylprednisolone 3Melphalan 3In Situ Hybridization, Fluorescence 3Gene Expression Profiling 3Early Intervention, Educational 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Extranodal NK-T-Cell × siplizumab × Clear all
NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 18 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡